News | July 05, 2023
CARE reaffirms A+ rating to IOL Chemicals and Pharmaceuticals
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Dr. Vivek joins Healthium after a stint at Ethicon, Johnson & Johnson
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The identified products for Active Pharmaceutical Ingredients (API) will be developed under the CRAMS and CDMO models
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
Exothera will manufacture Meissa’s MV-012-968 vaccine candidate under CGMP regulations to supply Phase 2 clinical trials
Subscribe To Our Newsletter & Stay Updated
